Lídia Blanco-Silvente

Lídia Blanco-Silvente

Auto-generated profile, based on publicly available information

Lídia Blanco-Silvente

TransLab Research Group, Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2017 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
LBLídia Blanco-Silvente
Lídia Blanco-Silvente
XCXavier Castells
Xavier Castells
MSMarc Saez
Marc Saez
MBMaria A Barceló
Maria A Barceló
JGJosep Garre-Olmo
Josep Garre-Olmo
DCDolors Capellà
Dolors Capellà
We investigated the effect of cholinesterase inhibitors on all-cause discontinuation, efficacy and safety, and the effects of study design-, intervention-, and patient-related covariates on the risk-benefit of cholinesterase inhibitors for Alzheimer’s disease. A systematic review and meta-analysis of randomized placebo-controlled clinical trials comparing cholinesterase inhibitors and placebo was performed. The effect of covariates on study outcomes was analysed by means of meta-regression using a Bayesian framework. Forty-three randomized placebo-controlled clinical trials involving 16106 patients were included. All-cause discontinuation was higher with cholinesterase inhibitors (OR = 1.66), as was discontinuation due to adverse events (OR=1.75). Cholinesterase inhibitors improved cognitive function (standardized mean difference = 0.38), global symptomatology (standardized mean difference=0.28) and functional capacity (standardized mean difference=0.16) but not neuropsychiatric symptoms. Rivastigmine was associated with a poorer outcome on all-cause discontinuation (Diff OR = 1.66) and donepezil with a higher efficacy on global change (Diff standardized mean difference = 0.41). The proportion of patients with serious adverse events decreased with age (Diff OR = -0.09). Mortality was lower with cholinesterase inhibitors than with placebo (OR = 0.65). While cholinesterase inhibitors show a poor risk-benefit relationship as indicated by mild symptom improvement and a higher than placebo all-cause discontinuation, a reduction of mortality was suggested. Intervention- and patient-related factors modify the effect of cholinesterase inhibitors in patients with Alzheimer’s disease.

24 July 2018 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
LBLídia Blanco-Silvente
Lídia Blanco-Silvente
DCDolors Capellà
Dolors Capellà
JGJosep Garre-Olmo
Josep Garre-Olmo
JVJoan Vilalta-Franch
Joan Vilalta-Franch
XCXavier Castells
Xavier Castells
The risk-benefit relationship of memantine treatment for Alzheimer’s disease (AD) remains unclear. In addition, variability between the results of clinical trials has been observed. The aim of this study was to investigate the risk-benefit relationship of memantine treatment in patients with AD and to determine the predictor effect of patient, intervention, and study design related covariates. A systematic review and meta-analysis of double-blind, placebo controlled clinical trials was performed. Primary outcomes were all-cause discontinuation, discontinuation due to adverse events (AE) and efficacy on cognitive function. Odds ratio (OR) and standard mean difference (SMD) with 95% confidence intervals were calculated. Meta-regression was conducted to identify related covariates. Cochrane Collaboration tool was used to evaluate the risk of bias of included trials. Eighteen studies involving 5004 patients were included. No differences between memantine and placebo were found for all-cause treatment discontinuation (OR=0.97 [0.82, 1.14]) and discontinuation due to AE (OR=1.18 [0.91, 1.53]). Memantine showed small improvement on cognitive function (SMD=0.15 [0.08, 0.22]). Baseline functional ability was positively associated with all-cause treatment discontinuation and discontinuation due to AE. Our study suggests that memantine has a very small efficacy on AD symptomatology and its safety profile is similar to that of placebo. No evidence of treatment discontinuation improvement with memantine is found, indicating a dubious risk-benefit relationship. No intervention characteristic or subgroup of patients clearly shows a significantly better risk-benefit relationship. CRD42014015696 .

2 January 2018 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
OTOriol Turró‐Garriga
Oriol Turró‐Garriga
LCLaia Calvó‐Perxas
Laia Calvó‐Perxas
JVJoan Vilalta‐Franch
Joan Vilalta‐Franch
LBLidia Blanco‐Silvente
Lidia Blanco‐Silvente
XCXavier Castells
Xavier Castells
OGon behalf of the Registry of Dementia of Girona Study Group (ReDeGi Study Group)
on behalf of the Registry of Dementia of Girona Study Group (ReDeGi Study Group)

1 August 2023 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
KAKristopher Amaro-Hosey
Kristopher Amaro-Hosey
XCXavier Castells
Xavier Castells
LBLidia Blanco-Silvente
Lidia Blanco-Silvente
PLPablo Loma-Osorio
Pablo Loma-Osorio
DCDolors Capellà
Dolors Capellà
Background: The risk of sudden cardiac death (SCD) can be increased with the use of drugs. However, it has been described heterogeneously in the literature. Objective: This study aims to systematically review epidemiological studies dealing with druginduced sudden death, describe their methodologies, and summarize the results found. Methods: A scoping review has been carried out using Medline electronic database. The search was limited up to 2020. Epidemiological studies were included, and case reports or case series were excluded. Results: Out of 3,114 potential articles, 74 were included. Most studies originated from North America (40.5%) or Europe (39.2%). Case-control (47.3%) or cohort (40.5%) studies were the most common designs. The data for outcomes and exposure were retrieved mainly from administrative databases (37.8%) or medical charts/hospital discharge reports (32.4%), but most studies used several sources of information. A composite variable of sudden death or SCD, mainly with ventricular arrhythmia, was the most frequently used endpoint. Only 18.9% of the studies included autopsy results to confirm the death. Psychotropic drugs were the most frequently studied. An increased risk of different outcomes for typical antipsychotics, tricyclic antidepressants, domperidone, and antiepileptics is suggested. Conclusion: The methodologies used were highly heterogeneous, and the results were, in general, not conclusive. An improvement of the methodologies is needed to achieve a conclusion regarding the risk of SCD associated with drug use.